USD
$0.00
(0.00%
)At Close (As of Oct 14, 2025)
$213.96M
Market Cap
-
P/E Ratio
-1.59
EPS
$5.39
52 Week High
$0.83
52 Week Low
HEALTHCARE
Sector
Field | Value (USD) |
---|---|
Total Assets | $157M |
Total Current Assets | $132M |
Cash And Cash Equivalents At Carrying Value | $19M |
Cash And Short Term Investments | $19M |
Inventory | - |
Current Net Receivables | - |
Total Non Current Assets | $25M |
Property Plant Equipment | - |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | $2.6M |
Intangible Assets Excluding Goodwill | $2.6M |
Goodwill | - |
Investments | - |
Long Term Investments | - |
Short Term Investments | $107M |
Other Current Assets | $5.5M |
Other Non Current Assets | - |
Total Liabilities | $36M |
Total Current Liabilities | $18M |
Current Accounts Payable | $4.9M |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | $2.9M |
Total Non Current Liabilities | $19M |
Capital Lease Obligations | $20M |
Long Term Debt | - |
Current Long Term Debt | - |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | $20M |
Other Current Liabilities | $9.9M |
Other Non Current Liabilities | - |
Total Shareholder Equity | $121M |
Treasury Stock | - |
Retained Earnings | -$364M |
Common Stock | $60K |
Common Stock Shares Outstanding | $58M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Pyxis Oncology, Inc. is a preclinical biotechnology firm based in Cambridge, Massachusetts, focused on advancing innovative therapies for cancer treatment through the development of antibody-drug conjugates (ADCs) and monoclonal antibodies (mAbs). With a commitment to harnessing the power of targeted therapies, Pyxis aims to enhance the efficacy and safety profiles of oncology treatments, addressing unmet medical needs in the oncology landscape. The company's cutting-edge research and strategic partnerships position it for potential breakthroughs in cancer therapy.